Previous 10 | Next 10 |
Exelixis (NASDAQ: EXEL ): Q4 Non-GAAP EPS of $0.26 beats by $0.05 ; GAAP EPS of $0.22 beats by $0.05 . Revenue of $240.3M (+5.1% Y/Y) misses by $3.39M . Shares -1.5% . Press Release More news on: Exelixis, Inc., Earnings news and commentary, Healthcare stocks news,
– Analysis for the co-primary endpoint of objective response rate and an interim analysis of progression-free survival expected in the second half of 2020 – Exelixis, Inc. (NASDAQ: EXEL) today announced enrollment of the first 100 patients in COSMIC-311, a phase 3 piv...
- Total Revenue of $240.3 Million for the Fourth Quarter of 2019, $967.8 Million for the Full Year 2019 - - GAAP Diluted EPS of $0.22 for the Fourth Quarter of 2019, $1.02 for the Full Year 2019 - - Non-GAAP Diluted EPS of $0.26 for the Fourth Quarter of 2019, $1.16 for the F...
Exelixis (NASDAQ: EXEL ) is scheduled to announce Q4 earnings results on Tuesday, February 25th, after market close. The consensus EPS Estimate is $0.17 (-54.1% Y/Y) and the consensus Revenue Estimate is $243.69M (+6.6% Y/Y). Over the last 2 years, EXEL has beaten EPS estimates 88% o...
– Conference Call and Webcast to Follow at 5:00 p.m. EST / 2:00 p.m. PST – Exelixis, Inc. (Nasdaq: EXEL) announced today that its fourth quarter and full year 2019 financial results will be released on Tuesday, February 25, 2020 after the markets close. At 5:00 p.m. E...
Exelixis (NASDAQ: EXEL) already markets cabozantinib as a treatment for kidney cancer and liver cancer; its latest results suggest it may secure approval for its use in prostate cancer someday, too. Interim results from a phase 1b trial showed that 32% of 44 metastatic castration-resistan...
Exelixis (NASDAQ: EXEL ) announces positive results from an open-label Phase 1b clinical trial, COSMIC-021 , evaluating the combination of Cabometyx (cabozantinib) and Roche's Tecentriq (atezolizumab) in patients with solid tumors. More news on: Exelixis, Inc., Ipsen S.A., Healthcare st...
Data from the COSMIC-021 trial will be presented on Thursday, February 13, 2020 at the American Society of Clinical Oncology’s Genitourinary Cancers Symposium Exelixis, Inc. (NASDAQ:EXEL) today announced encouraging results from the metastatic castration-resistant prostate c...
If there's one thing I've learned over my 21 years as an investor, it's that high-quality businesses often increase in value over time. While recessions and inevitable stock market corrections will occasionally test investors' resolve, the fact is that good companies tend to make investors money...
Presentations to be webcast on www.exelixis.com Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will be presenting at the following investor conferences in February: BIO CEO & Inves...
News, Short Squeeze, Breakout and More Instantly...
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2024 financial results will be released on Tuesday, August 6, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Ex...
2024-07-11 08:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...